{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:49:48Z","timestamp":1792457388714,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"DOI":"10.1007\/s11926-026-01224-0","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:32:25Z","timestamp":1778153545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of IgG4-Related Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Gabriela","family":"Hern\u00e1ndez-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Uriel","family":"Anaya-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mart\u00edn-Nares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"7","key":"1224_CR1","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2665-9913(24)00022-5","volume":"6","author":"G Katz","year":"2024","unstructured":"Katz G, Hernandez-Barco Y, Palumbo D, Guy TV, Dong L, Perugino CA. Proliferative features of IgG4-related disease. Lancet Rheumatol. 2024;6(7):e481\u201392. https:\/\/doi.org\/10.1016\/S2665-9913(24)00022-5.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"1224_CR2","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/art.39205","volume":"67","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67(9):2466\u201375. https:\/\/doi.org\/10.1002\/art.39205.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1224_CR3","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1111\/1756-185X.14802","volume":"26","author":"D Faz-Munoz","year":"2023","unstructured":"Faz-Munoz D, Mart\u00edn-Nares E, Hern\u00e1ndez-Delgado A, Hern\u00e1ndez-Molina G. Comorbidities and causes of hospitalizations in a cohort of IgG4-related disease patients from a single center. Int J Rheum Dis. 2023;26(11):2351\u20134. https:\/\/doi.org\/10.1111\/1756-185X.14802.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"1224_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae020","volume":"8","author":"ZS Wallace","year":"2024","unstructured":"Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract. 2024;8(2):rkae020. https:\/\/doi.org\/10.1093\/rap\/rkae020.","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"1224_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40266-024-01172-3","volume":"42","author":"M Akiyama","year":"2025","unstructured":"Akiyama M, Alshehri W, Saito K, Takeuchi T, Kaneko Y. Pharmacological management of IgG4-related disease: from traditional to mechanism-based targeted therapies. Drugs Aging. 2025;42(2):111\u201326. https:\/\/doi.org\/10.1007\/s40266-024-01172-3.","journal-title":"Drugs Aging"},{"issue":"19","key":"1224_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196774","volume":"14","author":"A Gonz\u00e1lez-Garc\u00eda","year":"2025","unstructured":"Gonz\u00e1lez-Garc\u00eda A, Starita-Fajardo G, Lucena L\u00f3pez D, Iranzo Alcolea MP, L\u00f3pez-Paraja M, Pe\u00f1a-Rodr\u00edguez M, et al. New developments in the treatment of IgG4-related disease: a comprehensive clinical approach. JCM. 2025;14(19):6774. https:\/\/doi.org\/10.3390\/jcm14196774.","journal-title":"JCM"},{"key":"1224_CR7","doi-asserted-by":"publisher","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis & Rheumatology. 2015;67(7):1688\u201399. https:\/\/doi.org\/10.1002\/art.39132","DOI":"10.1002\/art.39132"},{"key":"1224_CR8","doi-asserted-by":"publisher","unstructured":"Orozco-G\u00e1lvez O, Fern\u00e1ndez-Codina A, Lanzillotta M, Ebbo M, Schleinitz N, Culver EL, et al. Development of an algorithm for IgG4-related disease management. Autoimmunity Reviews. 2023;22(3):103273. https:\/\/doi.org\/10.1016\/j.autrev.2023.103273","DOI":"10.1016\/j.autrev.2023.103273"},{"issue":"6","key":"1224_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/2050640620934911","volume":"8","author":"JM L\u00f6hr","year":"2020","unstructured":"L\u00f6hr JM, Beuers U, Vujasinovic M, Alvaro D, Fr\u00f8kj\u00e6r JB, Buttgereit F, et al. European guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United European Gastroenterol J. 2020;8(6):637\u201366. https:\/\/doi.org\/10.1177\/2050640620934911.","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"1224_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00535-022-01857-9","volume":"57","author":"K Okazaki","year":"2022","unstructured":"Okazaki K, Kawa S, Kamisawa T, Ikeura T, Itoi T, Ito T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020. J Gastroenterol. 2022;57(4):225\u201345. https:\/\/doi.org\/10.1007\/s00535-022-01857-9.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1224_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pan.2016.12.003","volume":"17","author":"K Okazaki","year":"2017","unstructured":"Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17(1):1\u20136. https:\/\/doi.org\/10.1016\/j.pan.2016.12.003.","journal-title":"Pancreatology"},{"issue":"5","key":"1224_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14397595.2016.1259602","volume":"27","author":"Y Masaki","year":"2017","unstructured":"Masaki Y, Matsui S, Saeki T, Tsuboi H, Hirata S, Izumi Y, et al. A multicenter Phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod Rheumatol. 2017;27(5):849\u201354. https:\/\/doi.org\/10.1080\/14397595.2016.1259602.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"1224_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/1756-185X.13088","volume":"20","author":"Q Wu","year":"2017","unstructured":"Wu Q, Chang J, Chen H, Chen Y, Yang H, Fei Y, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int J Rheum Dis. 2017;20(5):639\u201346. https:\/\/doi.org\/10.1111\/1756-185X.13088.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"1224_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/rheumatology\/key227","volume":"58","author":"F Yunyun","year":"2019","unstructured":"Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology. 2019;58(1):52\u201360. https:\/\/doi.org\/10.1093\/rheumatology\/key227.","journal-title":"Rheumatology"},{"issue":"6","key":"1224_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.semarthrit.2020.01.010","volume":"50","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhao Z, Gao D, Wang H, Liao S, Dong C, et al. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial. Semin Arthritis Rheum. 2020;50(6):1513\u201320. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.01.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1224_CR16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s10067-023-06528-5","volume":"42","author":"Y Chen","year":"2023","unstructured":"Chen Y, Li R, Luo X, Wu T, Li J, Liu Z, et al. Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study. Clin Rheumatol. 2023;42(7):1839\u201346. https:\/\/doi.org\/10.1007\/s10067-023-06528-5.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"1224_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06520-5","volume":"7","author":"F Yunyun","year":"2017","unstructured":"Yunyun F, Yu C, Panpan Z, Hua C, Di W, Lidan Z, et al. Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep. 2017;7(1):6195. https:\/\/doi.org\/10.1038\/s41598-017-06520-5.","journal-title":"Sci Rep"},{"issue":"6","key":"1224_CR18","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, Witzig T, Wallace Z, Hart P, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206605.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1224_CR19","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","volume":"55","author":"Z Wallace","year":"2016","unstructured":"Wallace Z, Mattoo H, Mahajan V, Kulikova M, Lu L, Deshpande V, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology. 2016;55(6):1000\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kev438.","journal-title":"Rheumatology"},{"issue":"9","key":"1224_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","volume":"12","author":"M Ebbo","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, Groh M, Loundou A, Rogolet A, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844. https:\/\/doi.org\/10.1371\/journal.pone.0183844.","journal-title":"PLoS One"},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2020.12.006","volume":"84","author":"E Della-Torre","year":"2021","unstructured":"Della-Torre E, Lanzillotta M, Campochiaro C, et al. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. Eur J Intern Med. 2021;84:63\u20137. https:\/\/doi.org\/10.1016\/j.ejim.2020.12.006.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"1224_CR22","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/rheumatology\/keae675","volume":"64","author":"M Colquhoun","year":"2025","unstructured":"Colquhoun M, Barwick T, Bolton E, Gibson N, Hughes-Hallet A, et al. A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease. Rheumatology. 2025;64(5):2847\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keae675.","journal-title":"Rheumatology"},{"key":"1224_CR23","doi-asserted-by":"publisher","unstructured":"Lanzillotta M, Ramirez GA, Milani R, Dagna L, Della-Torre E. B-cells depletion after treatment with rituximab predicts relapse of IgG4-related disease. Rheumatology. 2025; 64(4): 2290\u201394. https:\/\/doi.org\/10.1093\/rheumatology\/keae248","DOI":"10.1093\/rheumatology\/keae248"},{"key":"1224_CR24","doi-asserted-by":"publisher","unstructured":"Goni E, Vikse J, Lanzillotta M, Fevang BT, Midtvedt \u00d8 Mahajne, et al. Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study of 115 patients. Eur J Intern Med. 2026;143:106459. https:\/\/doi.org\/10.1016\/j.ejim.2025.106459","DOI":"10.1016\/j.ejim.2025.106459"},{"issue":"1","key":"1224_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13075-018-1567-2","volume":"20","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang P, Wang M, Feng R, Lai Y, Peng L, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018;20(1):65. https:\/\/doi.org\/10.1186\/s13075-018-1567-2.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1224_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332392","volume":"20","author":"MK Yang","year":"2025","unstructured":"Yang MK, Ha SJ, Sa H-S. Comparison of volumetric responses to different corticosteroid administration methods in IgG4-related ophthalmic disease. PLoS One. 2025;20(11):e0332392. https:\/\/doi.org\/10.1371\/journal.pone.0332392.","journal-title":"PLoS One"},{"key":"1224_CR27","doi-asserted-by":"publisher","unstructured":"Yang MK, Kim GJ, Choi YA, Sa H-S. Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease. Hosohata K, editor. PLoS ONE. 2023;18(4):e0284442. https:\/\/doi.org\/10.1371\/journal.pone.0284442","DOI":"10.1371\/journal.pone.0284442"},{"key":"1224_CR28","doi-asserted-by":"publisher","unstructured":"Liu Y, Fu X, Zhang Y, Zheng Y, Jia J, Zheng Z, et al. Comparison of efficacy and safety of different medication protocols in patients with immunoglobulin G4\u2013related disease based on follow-up time: a systematic review and network meta-analysis. Archives of Rheumatology. 2026;41(1):3\u201313. https:\/\/doi.org\/10.5152\/ArchRheumatol.2026.25136","DOI":"10.5152\/ArchRheumatol.2026.25136"},{"key":"1224_CR29","doi-asserted-by":"publisher","unstructured":"Peng L, Nie Y, Zhou J, Wu L, Chen X, Wang F, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Annals of the Rheumatic Diseases. 2024;83(5):651\u201360. https:\/\/doi.org\/10.1136\/ard-2023-224487","DOI":"10.1136\/ard-2023-224487"},{"issue":"6","key":"1224_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/imj.13430","volume":"47","author":"Y Wang","year":"2017","unstructured":"Wang Y, Li K, Gao D, Luo G, Zhao Y, Wang X, et al. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review. Intern Med J. 2017;47(6):680\u20139. https:\/\/doi.org\/10.1111\/imj.13430.","journal-title":"Intern Med J"},{"issue":"10","key":"1224_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00535-021-01817-9","volume":"56","author":"Y Masaki","year":"2021","unstructured":"Masaki Y, Nakase H, Tsuji Y, Nojima M, Shimizu K, Mizuno N, et al. The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis. J Gastroenterol. 2021;56(10):869\u201380.0020. https:\/\/doi.org\/10.1007\/s00535-021-01817-9.","journal-title":"J Gastroenterol"},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"204062232110287","DOI":"10.1177\/20406223211028776","volume":"12","author":"J Zongfei","year":"2021","unstructured":"Zongfei J, Lijuan Z, Ying S, Dongmei L, Sifan W, Xiufang K, et al. Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry. Therapeutic Adv Chronic Disease. 2021;12:20406223211028776. https:\/\/doi.org\/10.1177\/20406223211028776.","journal-title":"Therapeutic Adv Chronic Disease"},{"issue":"4","key":"1224_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/25785826.2021.1886630","volume":"44","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M. B cell targeted therapy for immunoglobulin G4-related disease. Immunol Med. 2021;44(4):216\u201322. https:\/\/doi.org\/10.1080\/25785826.2021.1886630.","journal-title":"Immunol Med"},{"issue":"1","key":"1224_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/annrheumdis-2014-205233","volume":"74","author":"ZS Wallace","year":"2015","unstructured":"Wallace ZS, Mattoo H, Carruthers M, Mahahan V, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74(1):190\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205233.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1224_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/mr\/roac098","volume":"33","author":"M Lanzillotta","year":"2023","unstructured":"Lanzillotta M, Stone J, Della-Torre E. B-Cell depletion therapy in IgG4-related disease: state of the art and future perspectives. Mod Rheumatol. 2023;33(2):258\u201365. https:\/\/doi.org\/10.1093\/mr\/roac098.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1224_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.cgh.2007.12.020","volume":"6","author":"M Topazian","year":"2008","unstructured":"Topazian M, Witzig TE, Smyrk TC, Pulido J, Levy M, Kamath, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6(3):364\u20136. https:\/\/doi.org\/10.1016\/j.cgh.2007.12.020.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1224_CR37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.27435","volume":"62","author":"A Khosroshahi","year":"2010","unstructured":"Khosroshahi A, Bloch DB, Deshpande V, Stone J. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755\u201362. https:\/\/doi.org\/10.1002\/art.27435.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1224_CR38","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/jcm10061329","volume":"10","author":"J Backhus","year":"2021","unstructured":"Backhus J, Neuman C, Perkhofer L, Schulte LA, Mayer B, Seufferlein T, et al. A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab. J Clin Med. 2021;10(6):1329. https:\/\/doi.org\/10.3390\/jcm10061329.","journal-title":"J Clin Med"},{"issue":"8","key":"1224_CR39","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1136\/annrheumdis-2015-207625","volume":"74","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Awakawa T, Takahashi H. Is Rituximab effective for IgG4-related disease in the long term? Experience of cases treated with Rituximab for 4 years. Ann Rheum Dis. 2015;74(8):e46. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207625.","journal-title":"Ann Rheum Dis"},{"key":"1224_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejim.2019.12.029","volume":"74","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Lanzillottaa M, Bozzolob E, Baldisserab E, Milanic R, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Eur J Int Med. 2020;74:92\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2019.12.029.","journal-title":"Eur J Int Med"},{"issue":"12","key":"1224_CR41","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.cgh.2018.02.049","volume":"16","author":"S Majumder","year":"2018","unstructured":"Majumder S, Mohapatra S, Lennon RJ, Ramos G, Postier N, Gleeson F, et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol. 2018;16(12):1947\u201353. https:\/\/doi.org\/10.1016\/j.cgh.2018.02.049.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1224_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/kez380","volume":"59","author":"D Omar","year":"2020","unstructured":"Omar D, Chen Y, Cong Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology Oxford. 2020;59(4):718\u201326. https:\/\/doi.org\/10.1093\/rheumatology\/kez380.","journal-title":"Rheumatology Oxford"},{"key":"1224_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.006","volume":"127","author":"Y Liu","year":"2024","unstructured":"Liu Y, Jin K, Yang Y, Yang A. Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis. Eur J Intern Med. 2024;127:63\u201373. https:\/\/doi.org\/10.1016\/j.ejim.2024.06.006.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"1224_CR44","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.pan.2021.06.009","volume":"21","author":"M Lanzillotta","year":"2021","unstructured":"Lanzillotta M, Della-Torre E, Wallace ZS, Stone J, Karadag O, Fernandez-Codina A, et al. Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: a systematic review and meta-analysis. Pancreatology. 2021;21(7):1395\u2013401. https:\/\/doi.org\/10.1016\/j.pan.2021.06.009.","journal-title":"Pancreatology"},{"issue":"42","key":"1224_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012631","volume":"97","author":"R Wallwork","year":"2018","unstructured":"Wallwork R, Wallace Z, Perugino C, Sharma A, Stone J. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine Baltimore. 2018;97(42):e12631. https:\/\/doi.org\/10.1097\/MD.0000000000012631.","journal-title":"Medicine Baltimore"},{"issue":"8","key":"1224_CR46","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.0000000000000193","volume":"18","author":"A Haba","year":"2023","unstructured":"Haba A, Devresse A, Audard V, Boffa J, Karras A, Cartery C, et al. Clinical and prognostic factors in patients with IgG4-related kidney disease. Clin J Am Soc Nephrol. 2023;18(8):1031\u201340. https:\/\/doi.org\/10.2215\/CJN.0000000000000193.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1224_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/jnnp-2017-316519","volume":"89","author":"E Della-Torre","year":"2018","unstructured":"Della-Torre E, Campochiaro C, Cassione EB, Albano L, Gerevini S, Bianchi-Marzoli S, et al. Intrathecal rituximab for IgG -related hypertrophic pachymeningitis. J Neurol Neurosurg Psychiatry. 2018;89(4):441\u20134. https:\/\/doi.org\/10.1136\/jnnp-2017-316519.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1224_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1189778","volume":"14","author":"DT Balaban","year":"2023","unstructured":"Balaban DT, Hutto SK, Panzarini BP, O\u2019Shea A, Varma A, et al. Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report. Front Neurol. 2023;14:1189778. https:\/\/doi.org\/10.3389\/fneur.2023.1189778.","journal-title":"Front Neurol"},{"key":"1224_CR49","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.7861\/clinmed.2019-0457","volume":"20","author":"A Goodchild","year":"2020","unstructured":"Goodchild A, Peters R, Cargill T, Marint C, Fadipe A, Leandro D, et al. Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease. Clin Med. 2020;20:e32\u20139. https:\/\/doi.org\/10.7861\/clinmed.2019-0457.","journal-title":"Clin Med"},{"key":"1224_CR50","doi-asserted-by":"publisher","unstructured":"Baier E, Vaglio A. Novel and traditional B-cell depleting agents for IgG4-related disease: a critical view. Nephrol Dial Transplant. 2025, 40 (10), 1820\u201325. https:\/\/doi.org\/10.1093\/ndt\/gfaf108","DOI":"10.1093\/ndt\/gfaf108"},{"key":"1224_CR51","doi-asserted-by":"publisher","unstructured":"Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, et al. Inebilizumab for Treatment of IgG4-Related Disease. N Engl J Med. 2025;392(12):1168\u20131177. https:\/\/doi.org\/10.1056\/NEJMoa2409712","DOI":"10.1056\/NEJMoa2409712"},{"issue":"3","key":"1224_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40744-025-00763-9","volume":"12","author":"ZS Wallace","year":"2025","unstructured":"Wallace ZS, Park JY, Serra E, Gagnon-Sanschagrin P, Gu\u00e9rin A, Patterson K, et al. Burden of glucocorticoid use and risk of toxicities among patients with immunoglobulin-G4-related disease: a retrospective US-based claims study. Rheumatol Ther. 2025;12(3):547\u201360. https:\/\/doi.org\/10.1007\/s40744-025-00763-9.","journal-title":"Rheumatol Ther"},{"key":"1224_CR53","doi-asserted-by":"publisher","unstructured":"Tanaka Y, Umehara H, Sato H, Uchima K, Kouji K, Okazaki K. Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Mod Rheumatol. 2026;roag020. https:\/\/doi.org\/10.1093\/mr\/roag020.","DOI":"10.1093\/mr\/roag020"},{"key":"1224_CR54","unstructured":"https:\/\/www.tanabe-pharma.com\/en\/news\/news20251120140000\/main\/0\/link\/e_MTPC251120.pdf. Accessed 10 Mar 2026."},{"key":"1224_CR55","unstructured":"https:\/\/www.hspharm.com\/news\/news-detail-513345.htm. Accessed 10 Mar 2026."},{"issue":"5","key":"1224_CR56","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.41608","volume":"73","author":"AD Marinov","year":"2021","unstructured":"Marinov AD, Wang H, Bastacky SI, van Puijenbroek E, Schindler T, Speziale D, et al. The Type II Anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine Lupus model. Arthritis Rheumatol. 2021;73(5):826\u201336. https:\/\/doi.org\/10.1002\/art.41608.","journal-title":"Arthritis Rheumatol"},{"issue":"15","key":"1224_CR57","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Zuta Santill\u00e1n AE, et al. Efficacy and safety of obinutuzumab in active Lupus nephritis. N Engl J Med. 2025;392(15):1471\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2410965.","journal-title":"N Engl J Med"},{"key":"1224_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1624234","volume":"16","author":"W Wu","year":"2025","unstructured":"Wu W, Wang J, Chen S. Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases. Front Immunol. 2025;16:1624234. https:\/\/doi.org\/10.3389\/fimmu.2025.1624234.","journal-title":"Front Immunol"},{"issue":"4","key":"1224_CR59","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41433-023-02758-8","volume":"38","author":"H Sun","year":"2024","unstructured":"Sun H, Zeng X, Li Y, Li H, Yao X, Xue Y, et al. Successful remission induction of IgG4-related ophthalmic disease by obinutuzumab therapy: a retrospective study of 8 patients. Eye (Lond). 2024;38(4):723\u20139. https:\/\/doi.org\/10.1038\/s41433-023-02758-8.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1224_CR60","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ckj\/sfab250","volume":"15","author":"NE Ginth\u00f6r","year":"2021","unstructured":"Ginth\u00f6r NE, Artinger K, Pollheimer MJ, Stradner MH, Eller K. Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab. Clin Kidney J. 2021;15(3):564\u20136. https:\/\/doi.org\/10.1093\/ckj\/sfab250.","journal-title":"Clin Kidney J"},{"key":"1224_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejim.2023.07.019","volume":"116","author":"M Lanzillotta","year":"2023","unstructured":"Lanzillotta M, Mapelli P, Dagna L, Della-Torre E. B-cell depletion with obinutuzumab for the treatment of IgG4-related disease. Eur J Intern Med. 2023;116:155\u20136. https:\/\/doi.org\/10.1016\/j.ejim.2023.07.019.","journal-title":"Eur J Intern Med"},{"key":"1224_CR62","doi-asserted-by":"publisher","unstructured":"Zhu SH, Chen DQ, Zhang MC, Li Z, Cheng Z. Recurrent IgG4-related tubulointerstitial nephritis successfully treated with obinutuzumab: a case report and literature review. Kidney Med. 2025;8(1):101156. https:\/\/doi.org\/10.1016\/j.xkme.2025.101156","DOI":"10.1016\/j.xkme.2025.101156"},{"key":"1224_CR63","doi-asserted-by":"publisher","unstructured":"Perugino CA, Wallace ZS, Zack DJ, Quinn SM, Poma A, Fernandes AD, et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 2023;5(8):e442-e450. https:\/\/doi.org\/10.1016\/S2665-9913(23)00157-1.","DOI":"10.1016\/S2665-9913(23)00157-1"},{"issue":"1","key":"1224_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-006417","volume":"12","author":"A Santosa","year":"2026","unstructured":"Santosa A, Tan TC. CAR-T cell therapy for treatment-refractory rheumatic autoimmune diseases: a systematic review of clinical outcomes and safety profiles. RMD Open. 2026;12(1):e006417. https:\/\/doi.org\/10.1136\/rmdopen-2025-006417.","journal-title":"RMD Open"},{"key":"1224_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.11.027","author":"V Keitel","year":"2025","unstructured":"Keitel V, Kreissl MC, Goetze T, Dr\u00f6ge C, Kuhn CK, Pham NN, et al. CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.11.027. S0168-8278(25)02711-4.","journal-title":"J Hepatol"},{"key":"1224_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113779","volume":"145","author":"Y Sun","year":"2025","unstructured":"Sun Y, Huang S, Zhang B, Peng Y, Lu H, Jia Y, et al. Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease. Int Immunopharmacol. 2025;145:113779. https:\/\/doi.org\/10.1016\/j.intimp.2024.113779.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1224_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-026-03741-w","volume":"28","author":"J Hu","year":"2026","unstructured":"Hu J, Yu Y, Yang Y, Feng Y, Zhuang A, Jia R, et al. Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease. Arthritis Res Ther. 2026;28(1):47. https:\/\/doi.org\/10.1186\/s13075-026-03741-w.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1224_CR68","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/S2665-9913(25)00215-2","volume":"7","author":"S Cai","year":"2025","unstructured":"Cai S, Chen Y, Ye C, Hisanori U, Zhang J, Hu Z, et al. Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis. Lancet Rheumatol. 2025;7(12):e834\u20136. https:\/\/doi.org\/10.1016\/S2665-9913(25)00215-2.","journal-title":"Lancet Rheumatol"},{"key":"1224_CR69","doi-asserted-by":"publisher","unstructured":"Dalmas P, Galicier L, Ebbo M, Schleinitz N. Anti-BCMA CAR T-cell for IgG4-related disease: is this necessary? Lancet Rheumatol. 2026;S2665\u201399132600039\u20131. https:\/\/doi.org\/10.1016\/S2665-9913(26)00039-1.","DOI":"10.1016\/S2665-9913(26)00039-1"},{"issue":"1","key":"1224_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5\u201314. https:\/\/doi.org\/10.1111\/cea.13491.","journal-title":"Clin Exp Allergy"},{"key":"1224_CR71","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cyto.2018.05.009","volume":"110","author":"M Akiyama","year":"2018","unstructured":"Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease. Cytokine. 2018;110:416\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2018.05.009.","journal-title":"Cytokine"},{"issue":"12","key":"1224_CR72","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1080\/02770903.2021.2022158","volume":"59","author":"T Otani","year":"2022","unstructured":"Otani T, Iwamoto H, Yoshida Y, Yamaguchi K, Sakamoto S, Horimasu Y, et al. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report. J Asthma. 2022;59(12):2395\u2013401. https:\/\/doi.org\/10.1080\/02770903.2021.2022158.","journal-title":"J Asthma"},{"issue":"1","key":"1224_CR73","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13223-023-00825-z","volume":"19","author":"HS Jeon","year":"2023","unstructured":"Jeon HS, Jang JH, Lee Y, Park HS. Long-term efficacy of anti-IL-4 receptor antibody in a patient with aspirin-exacerbated respiratory disease and IgG4-related disease. Allergy Asthma Clin Immunol. 2023;19(1):67. https:\/\/doi.org\/10.1186\/s13223-023-00825-z.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"1224_CR74","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/life13030833","volume":"13","author":"TC Beck","year":"2023","unstructured":"Beck TC, Plante J, Robinson I, Khatskevich K, Forcucci JA, Valdebran M. Immunoglobulin G4-Related Disease-Associated Dermatitis with Pruritus: A Positive Response to Dupilumab. Life (Basel). 2023;13(3):833. https:\/\/doi.org\/10.3390\/life13030833.","journal-title":"Life (Basel)"},{"issue":"6","key":"1224_CR75","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1093\/rheumatology\/keab950","volume":"61","author":"I Nakajima","year":"2022","unstructured":"Nakajima I, Taniguchi Y, Tsuji H, Mizobuchi T, Fukuda K. Therapeutic potential of the interleukin-4\/interleukin-13 inhibitor dupilumab for treating IgG4-related disease. Rheumatology (Oxford). 2022;61(6):e151\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/keab950.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1224_CR76","doi-asserted-by":"publisher","first-page":"e003026","DOI":"10.1136\/rmdopen-2023-003026","volume":"9","author":"M Kanda","year":"2023","unstructured":"Kanda M, Kamekura R, Sugawara M, Nagahata K, Suzuki C, Takano K, et al. IgG4-related disease administered dupilumab: case series and review of the literature. RMD Open. 2023;9(1):e003026. https:\/\/doi.org\/10.1136\/rmdopen-2023-003026.","journal-title":"RMD Open"},{"issue":"9","key":"1224_CR77","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.55563\/clinexprheumatol\/nui493","volume":"43","author":"F Finet","year":"2025","unstructured":"Finet F, Ses\u00e9 L, Abad S, Walter O, Raherison-Semjen C, Aouba A, et al. Efficacy and glucocorticoid sparing of dupilumab in IgG4-related disease: a case series and literature review. Clin Exp Rheumatol. 2025;43(9):1661\u20136. https:\/\/doi.org\/10.55563\/clinexprheumatol\/nui493.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1224_CR78","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1093\/rheumatology\/kead680","volume":"63","author":"R Nishioka","year":"2024","unstructured":"Nishioka R, Ueno T, Inoue D, Kondo S, Kawano M. A case of IgG4-related dacryoadenitis and sialoadenitis remitted by dupilumab monotherapy. Rheumatology (Oxford). 2024;63(6):e188\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kead680.","journal-title":"Rheumatology (Oxford)"},{"key":"1224_CR79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jdcr.2024.03.007","volume":"64","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhao J, Liu L. A case of Dupilumab monotherapy in a patient with IgG4-related disease. JAAD Case Rep. 2024;64:106\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2024.03.007.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"1224_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/annrheumdis-2019-216368","volume":"79","author":"RS Simpson","year":"2020","unstructured":"Simpson RS, Lau SKC, Lee JK. Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis. 2020;79(4):549\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216368.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1224_CR81","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1136\/annrheumdis-2020-217010","volume":"81","author":"M Ebbo","year":"2022","unstructured":"Ebbo M, De Sainte-Marie B, Muller R, Piperoglou C, Grados A, V\u00e9ly F, et al. Correspondence on: \u201cDupilumab as a novel steroid-sparing treatment for IgG4-related disease\u201d by Simpson et al. Ann Rheum Dis. 2022;81(2):e26. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217010.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1224_CR82","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10735-018-9796-x","volume":"49","author":"R Yajima","year":"2018","unstructured":"Yajima R, Takano K, Konno T, Kohno T, Kaneko Y, Kakuki T, et al. Mechanism of fibrogenesis in submandibular glands in patients with IgG4-RD. J Mol Histol. 2018;49(6):577\u201387. https:\/\/doi.org\/10.1007\/s10735-018-9796-x.","journal-title":"J Mol Histol"},{"key":"1224_CR83","doi-asserted-by":"publisher","unstructured":"Zongfei J, Rongyi C, Xiaomeng C, Lili M, Lingying M, Xiufang K et al. In vitro IL-6\/IL-6R Trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease. Front Immunol. 2020;11:1272. https:\/\/doi.org\/10.3389\/fimmu.2020.01272","DOI":"10.3389\/fimmu.2020.01272"},{"issue":"4","key":"1224_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103296","volume":"22","author":"M Akiyama","year":"2023","unstructured":"Akiyama M, Hayashi Y, Suzuki K, Takeuchi T, Kaneko Y. Successful treatment of IgG4-related disease with tocilizumab monotherapy. Autoimmun Rev. 2023;22(4):103296. https:\/\/doi.org\/10.1016\/j.autrev.2023.103296.","journal-title":"Autoimmun Rev"},{"key":"1224_CR85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejim.2023.09.015","volume":"118","author":"V Batani","year":"2023","unstructured":"Batani V, Minici C, Sanvito F, Venturini E, Della-Torre E, IgG4-RD OSR Clinic. Interleukin-6 inhibition for the treatment of IgG4 related vasculitis. Eur J Intern Med. 2023;118:149\u201351. https:\/\/doi.org\/10.1016\/j.ejim.2023.09.015.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"1224_CR86","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1136\/annrheumdis-2016-209368","volume":"75","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Takahashi H, Takano K, Shimizu Y, Sakurai N, Suzuki C, et al. Efficacy of abatacept for IgG4-related disease over 8\u2005months. Ann Rheum Dis. 2016;75(8):1576\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209368.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1224_CR87","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2665-9913(21)00359-3","volume":"4","author":"MA Matza","year":"2022","unstructured":"Matza MA, Perugino CA, Harvey L, Fernandes AD, Wallace ZS, Liu H, et al. Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. Lancet Rheumatol. 2022;4(2):e105\u201312. https:\/\/doi.org\/10.1016\/S2665-9913(21)00359-3.","journal-title":"Lancet Rheumatol"},{"key":"1224_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106573","volume":"142","author":"C Minici","year":"2025","unstructured":"Minici C, Mahajne J, Orfanelli U, Lanzillotta M, Della-Torre E. Activation state of peripheral T lymphocytes predicts response to abatacept in patients with IgG4-related disease. Eur J Intern Med. 2025;142:106573. https:\/\/doi.org\/10.1016\/j.ejim.2025.106573.","journal-title":"Eur J Intern Med"},{"issue":"6","key":"1224_CR89","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/ard-2022-223529","volume":"82","author":"S Cai","year":"2023","unstructured":"Cai S, Hu Z, Chen Y, Chen Y, Ming B, Gao R, et al. BLyS\/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept. Ann Rheum Dis. 2023;82(6):881\u20133. https:\/\/doi.org\/10.1136\/ard-2022-223529.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1224_CR90","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.ard.2025.01.033","volume":"84","author":"Y Chen","year":"2025","unstructured":"Chen Y, Ye C, Yang P, Zhang W, Dai L, Wei W, et al. Thalidomide can effectively prevent relapse in IgG4-related disease outweighing its side effects: a multicentre, randomised, double-blinded, placebo-controlled study. Ann Rheum Dis. 2025;84(7):1246\u201352. https:\/\/doi.org\/10.1016\/j.ard.2025.01.033.","journal-title":"Ann Rheum Dis"},{"key":"1224_CR91","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ard.2025.05.199","volume":"84","author":"JH Stone","year":"2025","unstructured":"Stone JH, Martinez Valle F, Carruthers M, Baker M, Wu T, Choi J, et al. OP0186 efficacy and safety of rilzabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in patients with IgG4-related disease: results from a 52-week, phase 2, open-label, proof-of-concept study. Ann Rheum Dis. 2025;84:155.","journal-title":"Ann Rheum Dis"},{"key":"1224_CR92","unstructured":"Baker M, Horomanski A, Fairchild R, Liu Y, Diaz Deluna M, Lanz T et al. A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https:\/\/acrabstracts.org\/abstract\/a-phase-ii-single-site-open-label-study-of-zanubrutinib-in-patients-with-igg4-related-disease\/. Accessed March 14, 2026."},{"key":"1224_CR93","unstructured":"Stone J, Khosroshahi A, Majumder S, Perugino C, Fernandes A, McMahon G et al. Treatment of IgG4-Related Disease (IgG4-RD) with Elotuzumab, an Inhibitor of SLAM-F7: Report of a Phase 2 Clinical Trial [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https:\/\/acrabstracts.org\/abstract\/treatment-of-igg4-related-disease-igg4-rd-with-elotuzumab-an-inhibitor-of-slam-f7-report-of-a-phase-2-clinical-trial\/. Accessed March 14, 2026."},{"key":"1224_CR94","unstructured":"Xu X, Zhu H, Ye H. Tofacitinib Plus Glucocorticoids Can Effectively Reduce Relapse Rate in IgG4-Related Disease: A Randomized,Open-label controlled Trial [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https:\/\/acrabstracts.org\/abstract\/tofacitinib-plus-glucocorticoids-can-effectively-reduce-relapse-rate-in-igg4-related-disease-a-randomizedopen-label-controlled-trial\/. Accessed March 14, 2026."},{"issue":"11","key":"1224_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70065","volume":"14","author":"H Zhou","year":"2025","unstructured":"Zhou H, Zhao X, Chen R, Wang T, Zhuang Y, Liu Y. Coexistence of SAPHO syndrome and IgG4-related disease with Upadacitinib. Clin Transl Immunol. 2025;14(11):e70065. https:\/\/doi.org\/10.1002\/cti2.70065.","journal-title":"Clin Transl Immunol"},{"issue":"3","key":"1224_CR96","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2169\/internalmedicine.1862-23","volume":"63","author":"A Suenaga","year":"2024","unstructured":"Suenaga A, Sawa N, Oba Y, Ikuma D, Sekine A, Yamanouchi M, et al. Immunoglobulin G4-related dacryoadenitis successfully treated with Baricitinib. Intern Med. 2024;63(3):461\u20134. https:\/\/doi.org\/10.2169\/internalmedicine.1862-23.","journal-title":"Intern Med"},{"issue":"1","key":"1224_CR97","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/mrcr\/rxae047","volume":"9","author":"K Kusaka","year":"2025","unstructured":"Kusaka K, Nakayamada S, Hanami K, Nawata A, Tanaka Y. A case of Immunoglobulin G4-related disease complicated by atopic dermatitis responsive to upadacitinib treatment. Mod Rheumatol Case Rep. 2025;9(1):207\u201313. https:\/\/doi.org\/10.1093\/mrcr\/rxae047.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"1224_CR98","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/mrcr\/rxac002","volume":"6","author":"Y Fujita","year":"2022","unstructured":"Fujita Y, Iwata S, Nakano K, Nakayamada S, Miyazaki Y, Kawabe A, et al. A case of simultaneous onset of highly active Systemic Lupus Erythematosus and IgG4-related renal disease. Mod Rheumatol Case Rep. 2022;6(2):178\u201382. https:\/\/doi.org\/10.1093\/mrcr\/rxac002.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"3","key":"1224_CR99","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00296-023-05510-3","volume":"44","author":"M Iwamoto","year":"2024","unstructured":"Iwamoto M, Asashima H, Sugita T, Kawashima F, Sugita N, Rai A, et al. An overlapping case of IgG4-related disease and Systemic Lupus Erythematosus treated with belimumab: a case-based review. Rheumatol Int. 2024;44(3):549\u201356. https:\/\/doi.org\/10.1007\/s00296-023-05510-3.","journal-title":"Rheumatol Int"},{"issue":"10","key":"1224_CR100","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1093\/rheumatology\/keac284","volume":"61","author":"Y Katayama","year":"2022","unstructured":"Katayama Y, Katsuyama T, Shidahara K, Nawachi S, Asano Y, Ohashi K, et al. A case of recurrent IgG4-related disease successfully treated with belimumab after remission of Systemic Lupus Erythematosus. Rheumatology (Oxford). 2022;61(10):e308\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/keac284.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1224_CR101","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/0961203319840430","volume":"28","author":"M Yamamoto","year":"2019","unstructured":"Yamamoto M, Aochi S, Suzuki C, Nakamura S, Murakami R, Ogawa Y, et al. A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. Lupus. 2019;28(6):786\u20139. https:\/\/doi.org\/10.1177\/0961203319840430.","journal-title":"Lupus"},{"issue":"1","key":"1224_CR102","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1097\/IOP.0000000000000959","volume":"34","author":"S Jalaj","year":"2018","unstructured":"Jalaj S, Dunbar K, Campbell A, Kazim M. Treatment of pediatric IgG4-related orbital disease with TNF-\u03b1 inhibitor. Ophthalmic Plast Reconstr Surg. 2018;34(1):e10\u20132. https:\/\/doi.org\/10.1097\/IOP.0000000000000959.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"10","key":"1224_CR103","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1016\/j.radcr.2023.07.062","volume":"18","author":"A Mohammadzadeh","year":"2023","unstructured":"Mohammadzadeh A, Houshmand G, Pouraliakbar H, Soltani Z, Salehabadi G, Azimi A, et al. Coronary artery involvement in a patient with IgG4-related disease. Radiol Case Rep. 2023;18(10):3699\u2013703. https:\/\/doi.org\/10.1016\/j.radcr.2023.07.062.","journal-title":"Radiol Case Rep"},{"issue":"2","key":"1224_CR104","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/rheumatology\/keae448","volume":"64","author":"D Coulomb","year":"2025","unstructured":"Coulomb D, Szablewski V, Robert N, Dupuy AM, Berrahouane R, Goulabchand R, et al. A case of refractory IgG4-related disease successfully treated with daratumumab and lenalidomide. Rheumatology (Oxford). 2025;64(2):895\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keae448.","journal-title":"Rheumatology (Oxford)"},{"key":"1224_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.784520","volume":"8","author":"L Gan","year":"2021","unstructured":"Gan L, Luo X, Fei Y, Peng L, Zhou J, Li J, et al. Long-term outcomes of IgG4-related ophthalmic disease in a Chinese IgG4-related disease cohort. Front Med (Lausanne). 2021;8:784520. https:\/\/doi.org\/10.3389\/fmed.2021.784520.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1224_CR106","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jhbp.541","volume":"25","author":"K Kubota","year":"2018","unstructured":"Kubota K, Kamisawa T, Hirano K, Hirooka Y, Uchida K, Ikeura T, et al. Clinical course of type 1 autoimmune pancreatitis patients without steroid treatment: a Japanese multicenter study of 97 patients. J Hepatobiliary Pancreat Sci. 2018;25(4):223\u201330. https:\/\/doi.org\/10.1002\/jhbp.541.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"12","key":"1224_CR107","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/gut.2006.115246","volume":"56","author":"K Hirano","year":"2007","unstructured":"Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56(12):1719\u201324. https:\/\/doi.org\/10.1136\/gut.2006.115246.","journal-title":"Gut"},{"issue":"1","key":"1224_CR108","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-026-03743-8","volume":"28","author":"C Liao","year":"2026","unstructured":"Liao C, Huang Y, Shang G, Sun W, Cai S, Dong L. Reassessing the role of watchful waiting strategy for IgG4-related disease: a real-world study. Arthritis Res Ther. 2026;28(1):58. https:\/\/doi.org\/10.1186\/s13075-026-03743-8.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1224_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232089","volume":"15","author":"M Miyazawa","year":"2020","unstructured":"Miyazawa M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Matsuda K, et al. Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. PLoS One. 2020;15(4):e0232089. https:\/\/doi.org\/10.1371\/journal.pone.0232089.","journal-title":"PLoS One"},{"issue":"3","key":"1224_CR110","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.pan.2016.03.017","volume":"16","author":"Y Bi","year":"2016","unstructured":"Bi Y, Hart PA, Law R, Clain JE, Farnell MB, Gleeson FC, et al. Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting. Pancreatology. 2016;16(3):391\u20136. https:\/\/doi.org\/10.1016\/j.pan.2016.03.017.","journal-title":"Pancreatology"},{"issue":"8","key":"1224_CR111","doi-asserted-by":"publisher","first-page":"E912","DOI":"10.1055\/s-0042-111201","volume":"4","author":"H Matsubayashi","year":"2016","unstructured":"Matsubayashi H, Kishida Y, Iwai T, Murai K, Yoshida M, Imai K, et al. Transpapillary biliary stenting is a risk factor for pancreatic stones in patients with autoimmune pancreatitis. Endosc Int Open. 2016;4(8):E912\u20137. https:\/\/doi.org\/10.1055\/s-0042-111201.","journal-title":"Endosc Int Open"},{"issue":"1","key":"1224_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-04356-2","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Wei Y, Peng J, Zhao Y, Yao X, Zong Y. Does adjunctive endoscopic biliary drainage improve outcomes beyond glucocorticoids alone in IgG4-related pancreatobiliary disease? BMC Gastroenterol. 2025;25(1):789. https:\/\/doi.org\/10.1186\/s12876-025-04356-2.","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"1224_CR113","doi-asserted-by":"publisher","first-page":"E1410","DOI":"10.1055\/a-0966-8494","volume":"7","author":"Y Kuraishi","year":"2019","unstructured":"Kuraishi Y, Muraki T, Ashihara N, Ozawa M, Nakamura A, Watanabe T, et al. Validity and safety of endoscopic biliary stenting for biliary stricture associated with IgG4-related pancreatobiliary disease during steroid therapy. Endosc Int Open. 2019;7(11):E1410\u20138. https:\/\/doi.org\/10.1055\/a-0966-8494.","journal-title":"Endosc Int Open"},{"issue":"1","key":"1224_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02197-w","volume":"22","author":"L Peng","year":"2020","unstructured":"Peng L, Zhang P, Li J, Liu Z, Lu H, Zhu L, et al. IgG4-related aortitis\/periaortitis and periarteritis: a distinct spectrum of IgG4-related disease. Arthritis Res Ther. 2020;22(1):103. https:\/\/doi.org\/10.1186\/s13075-020-02197-w.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1224_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245601","volume":"16","author":"K Wang","year":"2021","unstructured":"Wang K, Wang Z, Zeng Q, Zhu L, Gao J, Wang Z, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One. 2021;16(2):e0245601. https:\/\/doi.org\/10.1371\/journal.pone.0245601.","journal-title":"PLoS One"},{"issue":"3","key":"1224_CR116","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/iju.12234","volume":"21","author":"S Mertens","year":"2014","unstructured":"Mertens S, Zeegers AG, Wertheimer PA, Hendriksz TR, van Bommel EF. Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction. Int J Urol. 2014;21(3):283\u20138. https:\/\/doi.org\/10.1111\/iju.12234.","journal-title":"Int J Urol"},{"issue":"1","key":"1224_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1432-8","volume":"19","author":"M Ozawa","year":"2017","unstructured":"Ozawa M, Fujinaga Y, Asano J, Nakamura A, Watanabe T, Ito T, et al. Clinical features of IgG4-related periaortitis\/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case-control study. Arthritis Res Ther. 2017;19(1):223. https:\/\/doi.org\/10.1186\/s13075-017-1432-8.","journal-title":"Arthritis Res Ther"},{"key":"1224_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.946675","volume":"9","author":"S Sultan","year":"2022","unstructured":"Sultan S, Acharya Y, Hezima M, Ramjohn J, Miresse D, Chua Vi Long K, et al. Management of retroperitoneal fibrosis with endovascular aneurysm repair in patients refractory to medical management. Front Surg. 2022;9:946675. https:\/\/doi.org\/10.3389\/fsurg.2022.946675.","journal-title":"Front Surg"},{"issue":"6","key":"1224_CR119","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/1526602817732316","volume":"24","author":"S Kasashima","year":"2017","unstructured":"Kasashima S, Kasashima F, Kawashima A, Endo M, Matsumoto Y, Kawakami K. Clinical outcomes after endovascular repair and open surgery to treat immunoglobulin G4-related and nonrelated inflammatory abdominal aortic aneurysms. J Endovasc Ther. 2017;24(6):833\u201345. https:\/\/doi.org\/10.1177\/1526602817732316.","journal-title":"J Endovasc Ther"},{"issue":"1","key":"1224_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03266-y","volume":"19","author":"T Hua","year":"2024","unstructured":"Hua T, Du J, Guo X, Peng L, Zhou J, Nie Y, et al. Coronary periarteritis and pericarditis are rare but distinct manifestations of heart involvement in IgG4-related disease: a retrospective cohort study. Orphanet J Rare Dis. 2024;19(1):266. https:\/\/doi.org\/10.1186\/s13023-024-03266-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1224_CR121","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytae492","volume":"8","author":"M Yamada","year":"2024","unstructured":"Yamada M, Ueno K, Kojima Y, Watanabe M, Morita N. Long-term efficacy of drug-coated balloon only angioplasty for IgG4-related coronary artery disease: a case report. Eur Heart J Case Rep. 2024;8(10):ytae492. https:\/\/doi.org\/10.1093\/ehjcr\/ytae492.","journal-title":"Eur Heart J Case Rep"},{"issue":"22","key":"1224_CR122","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehaf251","volume":"46","author":"K Usami","year":"2025","unstructured":"Usami K, Hiraya D, Ishizu T. Management of giant coronary artery aneurysm associated with immunoglobulin G4-related disease using covered stents. Eur Heart J. 2025;46(22):2129. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf251.","journal-title":"Eur Heart J"},{"issue":"1","key":"1224_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s44215-023-00063-0","volume":"2","author":"T Yokoyama","year":"2023","unstructured":"Yokoyama T, Suzuki R, Kurazumi H, Tanaka A, Kawano H, Mikamo A, et al. Open surgical treatment for aortic arch and coronary artery aneurysms associated with immunoglobulin G4-related disease: a case report. Gen Thorac Cardiovasc Surg Cases. 2023;2(1):47. https:\/\/doi.org\/10.1186\/s44215-023-00063-0.","journal-title":"Gen Thorac Cardiovasc Surg Cases"},{"key":"1224_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2026.152925","volume":"77","author":"F Carubbi","year":"2026","unstructured":"Carubbi F, Alunno A, Di Bartolomeo S, Carugno ME, Di Vincenzo F, Litterio M, et al. IgG4 related coronary artery involvement: a scoping review of the literature. Semin Arthritis Rheum. 2026;77:152925. https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152925.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"1224_CR125","doi-asserted-by":"publisher","first-page":"106859","DOI":"10.1016\/j.jaccas.2026","volume":"31","author":"J Ikram","year":"2026","unstructured":"Ikram J, Massad F, El Roumi J, Ehsan M, Villalonga M, Tabaja C, et al. IgG4-Related Pericarditis: Multimodality Imaging Diagnosis and Surgical Outcomes in a Case Series. JACC Case Rep. 2026;31(10):106859. https:\/\/doi.org\/10.1016\/j.jaccas.2026.","journal-title":"JACC Case Rep"},{"issue":"4","key":"1224_CR126","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1515\/rir-2025-0026","volume":"6","author":"J Zhang","year":"2025","unstructured":"Zhang J, Nie Y, Li J, Zhang N, Yang X, Jiang J, et al. Features of IgG4-related sclerosing mesenteritis: a Chinese cohort study and literature review. Rheumatol Immunol Res. 2025;6(4):210\u20139. https:\/\/doi.org\/10.1515\/rir-2025-0026.","journal-title":"Rheumatol Immunol Res"},{"issue":"1","key":"1224_CR127","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000295","volume":"4","author":"J Ominato","year":"2019","unstructured":"Ominato J, Oyama T, Cho H, Shiozaki N, Umezu H, Takizawa J, et al. The natural course of IgG4-related ophthalmic disease after debulking surgery: a single-centre retrospective study. BMJ Open Ophthalmol. 2019;4(1):e000295. https:\/\/doi.org\/10.1136\/bmjophth-2019-000295.","journal-title":"BMJ Open Ophthalmol"},{"issue":"2","key":"1224_CR128","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-024-01157-0","volume":"69","author":"R Iwasaki","year":"2025","unstructured":"Iwasaki R, Kitaguchi Y, Morimoto T, Nishida K. Postoperative outcomes of biopsy versus debulking surgery for immunoglobulin G4-related ophthalmic disease: a retrospective comparative study. Jpn J Ophthalmol. 2025;69(2):203\u201313. https:\/\/doi.org\/10.1007\/s10384-024-01157-0.","journal-title":"Jpn J Ophthalmol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01224-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01224-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:32:29Z","timestamp":1778153549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01224-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01224-0","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EMN reports speaker and advisory board fees from Amgen. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}